Concepedia

Gisle Langslet

GL

Statistics

Publications

47

Citations

6.7K

H-Index

32

Active since

2010

Affiliations

Oslo University Hospital(Current)

Amsterdam UMC Location University of Amsterdam

University of Oslo

Sanofi (France)

Regeneron (United States)

Gisle Langslet is an author at Oslo University Hospital specializing in familial hypercholesterolemia, lipid-lowering therapy, and pharmacotherapy.

ORCID

Publications per year

2010–2023

47

Publications

47

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text

, , +17

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 751 citations

, , +17

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet et al. · European Heart Journal · 2015 · 534 citations · Full text

, , +17

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine et al. · Journal of the American College of Cardiology · 2014 · 360 citations

, , +14

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun‐Ho Yoon, Pablo Arias et al. · Diabetes Care · 2014 · 223 citations · Full text

, , +14

1–5 of 47